BSE: ASPIRAPATH CMP: Rs 130.60 P/E: 2688.62x ROCE: 2.84% 6M Ret: +97.34% ATH: Rs 135.88 MCap: Rs 134.43 Cr
Key Performance Indicators
Aspira Pathlab trades at Rs 130.60 on BSE (ticker: ASPIRAPATH), with a market capitalisation of Rs 134.43 crore. The price-to-earnings ratio is 2688.62x. Return on capital employed stands at 2.84%. The six-month price return is +97.34%. The company reported a quarterly net loss of Rs 0.69 crore, a year-on-year change of -195.83%. Quarterly sales are Rs 6.52 crore (+12.80% year-on-year). The all-time high is Rs 135.88, above the current price by 4.0%.
Highlights
Aspira Pathlab has delivered a six-month return of 97.34%, positioning it among the notable performers over the measured period in the healthcare sector. The all-time high of Rs 135.88 stands 4.0% above the current price of Rs 130.60, indicating the stock has corrected from its peak and sits below its historical ceiling. The market capitalisation of Rs 134.43 crore at the current price classifies this as a small-cap entity.
At a P/E of 2688.62x, the stock trades at an extreme premium to the Indian market average — reflecting very high growth expectations or thin absolute earnings amplifying the mathematical multiple. The ROCE of 2.84% — a low positive or negative reading requiring monitoring for improvement — provides a capital efficiency perspective that complements the P/E valuation framework.
Business Overview
Aspira Pathlab and Diagnostics is a diagnostic laboratory chain providing pathology testing, radiology, and preventive health check services in Maharashtra. Diagnostic companies serve patients through walk-in collections, home sample collection, doctor-referred tests, and corporate health check programmes. India's diagnostics market has been growing with rising healthcare awareness, expanding health insurance coverage, and the post-pandemic normalisation of preventive health testing.
The P/E of 2,688.62 times on a quarterly net loss of Rs 0.69 crore reveals a company in near-breakeven territory — the extreme P/E reflects prior trailing positive earnings that have now turned to a marginal loss. The quarterly revenue growth of 12.80% to Rs 6.52 crore shows steady top-line expansion. The ROCE of 2.84% is positive, indicating improving capital efficiency. The six-month return of 97.34% and the all-time high of Rs 135.88 — just Rs 5.28 above the current price of Rs 130.60 — confirm sustained investor confidence close to the historical peak.
Financial Analysis
Aspira Pathlab's financial profile for the most recently reported quarter shows quarterly revenue of Rs 6.52 crore (+12.80% year-on-year) and quarterly net loss of Rs 0.69 crore (-195.83% variation year-on-year). The current quarterly loss position means valuation is entirely forward-looking — dependent on the company's demonstrated trajectory toward profitability and the credibility of the timeline for achieving breakeven and beyond.
The ROCE of 2.84% is in the low-positive or negative range, which requires monitoring to assess whether the business model can generate returns above the cost of capital at scale.
At Rs 134.43 crore market capitalisation, Aspira Pathlab operates in the small-cap space where institutional coverage may be limited but trading liquidity is practical for retail and smaller institutional investors. Investors should access the company's quarterly results on BSE and any investor presentations for a comprehensive fundamental assessment.
Investor Highlights
The investment case for Aspira Pathlab is anchored in the healthcare sector's structural growth dynamics in India — expanding health insurance coverage, rising disease awareness, and government healthcare investment — combined with the company-specific momentum reflected in the 97.34% six-month return.
With the current price 4.0% below the all-time high of Rs 135.88, the stock presents a different risk-reward profile than entry at the peak. The key analytical question is whether the correction from the high represents a value opportunity — supported by maintained or improving fundamental performance — or an ongoing normalisation from a prior speculative overshoot.
The current quarterly loss position means the investment decision is substantially forward-looking. Access to the company's management commentary — available through quarterly results conference calls, exchange presentations, and annual report strategic sections — is essential for forming a credible view on the profitability path and timeline.
Frequently Asked Questions
Q: What does Aspira Pathlab do and what sector does it operate in?
A: Aspira Pathlab operates in India's healthcare sector, listed on BSE under ticker ASPIRAPATH. The company's specific products, services, and revenue model are documented in its annual report and exchange filings available through the BSE portal at bseindia.com. Investors should read these documents to form an accurate business understanding before drawing investment conclusions from price performance.
Q: What explains the six-month return of 97.34% for Aspira Pathlab?
A: The 97.34% six-month return reflects a combination of positive sector-level sentiment in the healthcare space, company-specific operational improvements visible in the financial data, and market re-rating of the company's growth potential. The re-rating has occurred despite current quarterly losses, suggesting investors are pricing future earnings improvements rather than current profitability. Specific fundamental triggers — contract wins, capacity additions, or strategic announcements — should be verified through BSE exchange disclosures.
Q: How should investors interpret the ROCE of 2.84% for Aspira Pathlab?
A: Return on capital employed of 2.84% measures the pre-tax profit generated per rupee of total capital deployed in the business. At 2.84%, the return on capital is low or marginally positive. Investors should monitor whether the ROCE is trending higher as revenues scale and operating leverage takes effect, or whether structural challenges in the business model limit returns.
Q: What is Aspira Pathlab's current P/E and all-time high?
A: Aspira Pathlab trades at a price-to-earnings multiple of 2688.62x at the current price of Rs 130.60. The all-time high price is Rs 135.88, which is 4.0% above the current price — indicating the stock has corrected from its historical peak.
Q: Where can investors find Aspira Pathlab's official financial data?
A: Aspira Pathlab's quarterly results, annual reports, shareholding patterns, and all material corporate disclosures are filed with the BSE and are freely available through the BSE corporate filing portal at bseindia.com. SEBI's listing regulations mandate disclosure of all financial results, board decisions, and significant corporate events within prescribed timelines. These filings are the authoritative source of verified financial and operational data for investment analysis.